Devyser Diagnostics AB has secured a CFTR NGS proposal with UNC Hospitals. The proposal with UNC Hospitals is valid for a period of up to four years. Indicative order value is estimated to be approximately SEK 2.5 million annually.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
99 SEK | +5.77% | +0.20% | +25.95% |
May. 08 | Transcript : Devyser Diagnostics AB, Q1 2024 Earnings Call, May 08, 2024 | |
May. 08 | Devyser Diagnostics AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.95% | 141M | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- DVYSR Stock
- News Devyser Diagnostics AB
- Devyser Diagnostics AB Achieves Breakthrough in the US with Cystic Fibrosis NGS Test